Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kalpana L"'
Autor:
Vessies DCL; Department of Laboratory Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Schuurbiers MMF; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Schouten I; Department of Thoracic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Linders TC; Department of Laboratory Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Lanfermeijer M; Department of Laboratory Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Ramkisoensing KL; Department of Laboratory Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hartemink KJ; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Publikováno v:
Molecular oncology [Mol Oncol] 2022 Jul; Vol. 16 (14), pp. 2719-2732. Date of Electronic Publication: 2022 Jun 27.
Autor:
Vessies DCL; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands., Linders TC; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lanfermeijer M; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ramkisoensing KL; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., Schouten RD; Department of Pulmonology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, the Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Publikováno v:
Clinical chemistry [Clin Chem] 2021 Jul 06; Vol. 67 (7), pp. 959-967.
Autor:
Daan C. L. Vessies, Milou M. F. Schuurbiers, Vincent van der Noort, Irene Schouten, Theodora C. Linders, Mirthe Lanfermeijer, Kalpana L. Ramkisoensing, Koen J. Hartemink, Kim Monkhorst, Michel M. van den Heuvel, Daan van den Broek
Publikováno v:
Molecular oncology, 16(14), 2719-2732. Elsevier
Molecular Oncology, 16, 2719-2732
Molecular Oncology, 16, 14, pp. 2719-2732
Vessies, D C L, Schuurbiers, M M F, van der Noort, V, Schouten, I, Linders, T C, Lanfermeijer, M, Ramkisoensing, K L, Hartemink, K J, Monkhorst, K, van den Heuvel, M M & van den Broek, D 2022, ' Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients ', Molecular oncology, vol. 16, no. 14, pp. 2719-2732 . https://doi.org/10.1002/1878-0261.13267
Molecular Oncology, 16, 2719-2732
Molecular Oncology, 16, 14, pp. 2719-2732
Vessies, D C L, Schuurbiers, M M F, van der Noort, V, Schouten, I, Linders, T C, Lanfermeijer, M, Ramkisoensing, K L, Hartemink, K J, Monkhorst, K, van den Heuvel, M M & van den Broek, D 2022, ' Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients ', Molecular oncology, vol. 16, no. 14, pp. 2719-2732 . https://doi.org/10.1002/1878-0261.13267
Contains fulltext : 288326.pdf (Publisher’s version ) (Open Access) Stage II-IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard-of-care treatment, even though only approximately 5.8% of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e9d82a75f2ef699ab5897fc74a45ce
https://research.vumc.nl/en/publications/172b8a42-bc2a-4621-811a-564732644516
https://research.vumc.nl/en/publications/172b8a42-bc2a-4621-811a-564732644516